{"id":"pmc:PMC13697276","kind":"article","title":"Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial","authors":["Almandoz J","Miras A","Blüher M","Orozco Del Pino P","Mojdami D","Batterham R","Trice K","Goebel B","Tangi F"],"author_count":9,"year":2026,"published":"2026-10-14","venue":"Obesity pillars","cited_by":0,"doi":null,"arxiv_id":null,"nct_id":null,"source_url":"https://europepmc.org/article/PMC/PMC13697276","archive_url":"https://space-kitty.com/papers/pmc:PMC13697276","updated":null,"pmid":null,"pmcid":"PMC13697276","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13697276/pdf","abstract":null,"abstract_license":null,"license":"CC-BY","is_open_access":true,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Metadata: Europe PMC (EMBL-EBI).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}